References:
1. Piaścik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki
J, Gabryelewicz A. The results of severe acute pancreatitis treatment
with continuous regional arterial infusion of protease inhibitor and
antibiotic: a randomized controlled study. PANCREAS 2010; 39: 863-67.
2. UK W, Association OUGS, Working POTB, Association OSOG, Pancreatic
SOGB, UK WPOA. UK guidelines for the management of acute pancreatitis.
GUT 2005; 54: i1-09.
3. Mofidi R, Madhavan KK, Garden OJ, Parks RW. An audit of the
management of patients with acute pancreatitis against national
standards of practice. BRIT J SURG 2007; 94: 844-48.
4. Isaji S, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M,
Sekimoto M, Hirota M, Kimura Y, Takeda K, Koizumi M, Otsuki M, Matsuno
S, JPN. JPN Guidelines for the management of acute pancreatitis:surgical
management. Journal of Hepato-Biliary-Pancreatic Surgery 2006; 13:
48-55.
5. Xue P, Deng LH, Xia Q, Zhang ZD, Hu WM, Yang XN, Song B, Huang ZW.
Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in
early stage. World J Gastroenterol 2008; 14: 474-78.
6. Beger HG, Rau B, Mayer J, Pralle U. Natural course of acute
pancreatitis. WORLD J SURG 1997; 21: 130-35.
7. Leppaniemi A, Tolonen M, Tarasconi A, Segovia-Lohse H, Gamberini E,
Kirkpatrick AW, Ball CG, Parry N, Sartelli M, Wolbrink D, van Goor H,
Baiocchi G, Ansaloni L, Biffl W, Coccolini F, Di Saverio S, Kluger Y,
Moore E, Catena F. 2019 WSES guidelines for the management of severe
acute pancreatitis. WORLD J EMERG SURG 2019; 14: 27.
8. Reuken PA, Albig H, Rodel J, Hocke M, Will U, Stallmach A, Bruns T.
Fungal Infections in Patients With Infected Pancreatic Necrosis and
Pseudocysts: Risk Factors and Outcome. PANCREAS 2018; 47: 92-98.
9. Behrman SW, Bahr MH, Dickson PV, Zarzaur BL. The microbiology of
secondary and postoperative pancreatic infections: implications for
antimicrobial management. Arch Surg 2011; 146: 613-19.
10. Levine DP. Vancomycin: a history. CLIN INFECT DIS 2006; 42 Suppl 1:
S5-12.
11. Bailie GR, Yu R, Morton R, Waldek S. Vancomycin, red neck syndrome,
and fits. LANCET 1985; 2: 279-80.
12. Cole DR, Oliver M, Coward RA, Brown CB. Allergy, red man syndrome,
and vancomycin. LANCET 1985; 2: 280.
13. Garrelts JC, Peterie JD. Vancomycin and the ”red man’s syndrome”. N
Engl J Med 1985; 312: 245.
14. Bergman MM, Glew RH, Ebert TH. Acute interstitial nephritis
associated with vancomycin therapy. Arch Intern Med 1988; 148: 2139-40.
15. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of
serum antibiotic concentrations to nephrotoxicity in cancer patients
receiving concurrent aminoglycoside and vancomycin therapy. AM J MED
1987; 83: 1091-97.
16. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of
vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother
1990; 25: 679-87.
17. Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DF. Mississippi Mud
No More: Cost‐Effectiveness of Pharmacokinetic Dosage Adjustment of
Vancomycin to Prevent Nephrotoxicity. Pharmacotherapy: The Journal of
Human Pharmacology and Drug Therapy 2003; 23: 643-50.
18. Traber PG, Levine DP. Vancomycin Ototoxicity in patient with normal
renal function. ANN INTERN MED 1981; 95: 458-60.
19. Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, Li DK, Liu YN, Yang
KH, Zhang YY, Zhai SD. Therapeutic drug monitoring of vancomycin: a
guideline of the Division of Therapeutic Drug Monitoring, Chinese
Pharmacological Society. J Antimicrob Chemother 2016; 71: 3020-25.
20. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA,
Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro
BM. Therapeutic monitoring of vancomycin for serious
methicillin-resistant Staphylococcus aureus infections: A revised
consensus guideline and review by the American Society of Health-System
Pharmacists, the Infectious Diseases Society of America, the Pediatric
Infectious Diseases Society, and the Society of Infectious Diseases
Pharmacists. AM J HEALTH-SYST PH 2020; 77: 835-64.
21. Burns GP, Stein TA, Kabnick LS. Blood-pancreatic juice barrier to
antibiotic excretion. AM J SURG 1986; 151: 205-08.
22. Brattström C, Malmborg A, Tydén G. Penetration of Imipenem into
Human Pancreatic Juice following Single Intravenous Dose
Administration1. CHEMOTHERAPY 1989; 35: 83-87.
23. Wittau M, Wagner E, Kaever V, Koal T, Henne-Bruns D, Isenmann R.
Intraabdominal tissue concentration of ertapenem. The Journal of
antimicrobial chemotherapy 2006; 57: 312-16.
24. Schubert S, Dalhoff A. Activity of Moxifloxacin, Imipenem, and
Ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus
faecalis, and Bacteroides fragilis in Monocultures and Mixed Cultures in
an In Vitro Pharmacokinetic/Pharmacodynamic Model Simulating
Concentrations in the Human Pancreas. ANTIMICROB AGENTS CH 2012; 56:
6434-36.
25. Wacke R, Forster S, Adam U, Mundkowski RG, Klar E, Hopt UT, Drewelow
B. Penetration of moxifloxacin into the human pancreas following a
single intravenous or oral dose. J ANTIMICROB CHEMOTH 2006; 58: 994-99.
26. He N, Yan YY, Ying YQ, Yi M, Yao GQ, Ge QG, Zhai SD.
[Individualized vancomycin dosing for a patient diagnosed as severe
acute pancreatitis with concurrent extracorporeal membrane oxygenation
and continuous veno-venous hemofiltration therapy: a case report].
Beijing Da Xue Xue Bao Yi Xue Ban 2018; 50: 915-20.
27. McConeghy KW, Liao S, Clark D, Worboys P, Barriere SL, Rodvold KA.
Variability in telavancin cross-reactivity among vancomycin
immunoassays. Antimicrob Agents Chemother 2014; 58: 7093-97.
28. Hooker AC, Staatz CE, Karlsson MO, Medicinska OFV, Institutionen
FFB, Uppsala U, Avdelningen FFOL, Farmaceutiska F. Conditional Weighted
Residuals (CWRES): A Model Diagnostic for the FOCE Method. PHARM
RES-DORDR 2007; 24: 2187-97.
29. Ma N, Cui DJ, Lv GP, Deng Q. The penetration of antibiotics into the
lung,liver,kidney and pancreas and their tissue bactericidal indexes.
Tianjin Med J 2000; 28: 288-90.
30. M. Falconi PPGC. Facing the Pancreatic Dilemma: Springer Berlin
Heidelberg, 1994.
31. He J, Mao E, Feng J, Jiang H, Yang W, Chen E. The pharmacokinetics
of vancomycin in patients with severe acute pancreatitis. EUR J CLIN
PHARMACOL 2016; 72: 697-702.
32. VANCOMYCIN. vancomycin injection, solution, Xellia Pharmaceuticals
USA LLC.(2019).
Table1. Pharmacokinetic parameters estimated for vancomycin.